- Home
- KIO vs CLLS Comparison
KIO vs CLLS Comparison
Compare KIO & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KIO | CLLS |
|---|---|---|
| Founded | N/A | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.8M | 394.4M |
| IPO Year | 2011 | 2014 |
Fundamental Metrics
Financial Performance| Metric | KIO | CLLS |
|---|---|---|
| Price | $10.04 | $1.08 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.83 |
| AVG Volume (30 Days) | ★ 339.8K | 90.6K |
| Earning Date | 01-01-0001 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.70 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.70 | $0.88 |
| 52 Week High | $12.12 | $5.45 |
Technical Indicators
Market Signals| Indicator | KIO | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 41.47 | 39.52 |
| Support Level | $9.74 | $0.88 |
| Resistance Level | $11.26 | $2.99 |
| Average True Range (ATR) | 0.11 | 0.10 |
| MACD | 0.04 | 0.06 |
| Stochastic Oscillator | 70.97 | 52.40 |
Price Performance
Historical ComparisonAbout KIO KKR Income Opportunities Fund
KKR Income Opportunities Fund operates as a closed-end registered management investment company. The Fund's main objective is to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in a portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.